Annexon_Logo_RGB.png
Annexon To Present Pivotal Phase 3 Data On Early And Durable Benefits With First-In-Class C1q Blocking Antibody ANX005 In Guillain-Barré Syndrome At 2024 PNS Annual Meeting
June 18, 2024 08:00 ET | Annexon Biosciences
Single Infusion of ANX005 Demonstrated Significant Improvements Across Multiple Functional and Prognostic Measures That Expedited Recovery in GBS Patients ANX005 Has Potential to be the First...
Annexon_Logo_RGB.png
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
June 17, 2024 16:05 ET | Annexon Biosciences
BRISBANE, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living...
Annexon_Logo_RGB.png
Annexon Announces Pricing of $125 Million Underwritten Public Offering
June 05, 2024 23:04 ET | Annexon Biosciences
BRISBANE, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with...
Annexon_Logo_RGB.png
Annexon Announces Proposed Public Offering of Common Stock
June 04, 2024 17:06 ET | Annexon Biosciences
BRISBANE, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with...
Annexon_Logo_RGB.png
Annexon Announces Positive Topline Results from Pivotal Phase 3 Trial for First-in-Class C1q Blocking Antibody ANX005 in Guillain-Barré Syndrome
June 04, 2024 07:00 ET | Annexon Biosciences
Single Infusion of ANX005 30 mg/kg Met Primary Endpoint, Delivering a Highly Statistically Significant and Clinically Meaningful 2.4-fold Improvement in GBS-DS vs. Placebo at Week 8, p=0.0058 ANX005...
Annexon_Logo_RGB.png
Annexon Biosciences to Host Conference Call and Webcast to Discuss GBS Phase 3 Data
June 03, 2024 16:30 ET | Annexon Biosciences
BRISBANE, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living...
Annexon_Logo_RGB.png
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
May 16, 2024 16:05 ET | Annexon Biosciences
BRISBANE, Calif., May 16, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living...
Annexon_Logo_RGB.png
Annexon Reports First Quarter 2024 Financial Results and Key Anticipated Milestones
May 13, 2024 08:00 ET | Annexon Biosciences
Multiple Value-creating Catalysts Across the Annexon Portfolio Throughout 2024 Pivotal Phase 3 Data for ANX005 in Guillain-Barré Syndrome (GBS) Expected in Second Quarter 2024; Potential to be the...
Annexon_Logo_RGB.png
Annexon Biosciences to Present at the Bank of America Health Care Conference
May 09, 2024 08:00 ET | Annexon Biosciences
BRISBANE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with...
Annexon_Logo_RGB.png
Annexon Presents New Neuroprotection Data Showing ANX007 Protects Vision and Vision-Associated Structures in Geographic Atrophy at ARVO 2024 Annual Meeting
May 07, 2024 12:30 ET | Annexon Biosciences
ANX007 demonstrated significant, broad-based protection from vision loss in foveal and non-foveal patients, and in low light settings ANX007 protected key retinal structures important for vision:...